This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

• To assess the clinical benefits and harms of interleukin-receptor antagonists and tumor necrosis factor (TNF) inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.

• To determine whether interleukin-receptor antagonists or TNF inhibitors, provided to people both with and without pre‐existing cardiovascular disease, are:

  • useful in preventing adverse cardiovascular outcomes; and

  • safe.